TABLE 4.
Baseline, mean (SE) | End of period, mean (SE) | Change from baseline, mean (95% CI) | DASH‐Losartan versus control‐placebo, mean (95% CI) | P | |
---|---|---|---|---|---|
Overall, N = 55 (107 measurements) | |||||
Control‐placebo, N = 28 | 5.36 (0.22) | 5.19 (0.22) | −0.16 (−0.40, 0.07) | Referent | Referent |
DASH‐Losartan, N = 27 | 5.00 (0.23) | 4.56 (0.20) | −0.44 (−0.73, −0.15) | −0.28 (−0.65, 0.10) | 0.15 |
Baseline serum urate < 6 mg/dL, N = 39 (77 measurements) | |||||
Control‐Placebo, N = 18 | 4.68 (0.17) | 4.62 (0.19) | −0.05 (−0.35, 0.24) | Referent | Referent |
DASH‐Losartan, N = 21 | 4.53 (0.19) | 4.30 (0.19) | −0.22 (−0.48, 0.03) | −0.17 (−0.56, 0.22) | 0.39 |
Baseline serum urate ≥6 mg/dL, N = 15 (29 measurements) | |||||
Control‐Placebo, N = 9 | 6.74 (0.14) | 6.38 (0.26) | −0.37 (−0.76, 0.02) | Referent | Referent |
DASH‐Losartan, N = 6 | 6.67 (0.28) | 5.40 (0.47) | −1.27 (−1.94, −0.59) | ‐0.90 (−1.68, −0.12) | 0.024 |
The P‐value for an interaction between diet and losartan overall was 0.72.
The P‐value for an interaction across strata of baseline serum urate using a Wald test was 0.015.